SEC Form 4 · accession 0001209059-26-000006
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dino A Rossi
Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 14, 2026 · 6:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2026 | G | 3,691 | $0.00 | D | 75,000 | D | |
| Common StockF2 | Aug 14, 2026 | S | 341 | $325.5985 | D | 74,659 | D | |
| Common StockF3 | Aug 14, 2026 | S | 2,287 | $326.6028 | D | 72,372 | D | |
| Common StockF4 | Aug 14, 2026 | S | 5,226 | $327.3939 | D | 67,146 | D | |
| Common StockF5 | Aug 14, 2026 | S | 1,687 | $328.5152 | D | 65,459 | D | |
| Common StockF6 | Aug 14, 2026 | S | 7,428 | $329.6015 | D | 58,031 | D | |
| Common StockF7 | Aug 14, 2026 | S | 4,896 | $330.3558 | D | 53,135 | D | |
| Common StockF8 | Aug 14, 2026 | S | 3,095 | $331.4333 | D | 50,040 | D | |
| Common Stock | Aug 14, 2026 | S | 40 | $333.23 | D | 50,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund.
- F2The transaction was executed in multiple trades ranging from $325 to $325.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F3The transaction was executed in multiple trades ranging from $326.04 to $326.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F4The transaction was executed in multiple trades ranging from $327 to $327.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F5The transaction was executed in multiple trades ranging from $328.01 to $328.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F6The transaction was executed in multiple trades ranging from $329.01 to $329.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F7The transaction was executed in multiple trades ranging from $330 to $330.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F8The transaction was executed in multiple trades ranging from $331.02 to $331.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.